Planning Strategies’s AbbVie ABBV Stock Holding History

Planning Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$264K	Buy	1,010 +9	+0.9%	+$2.31K	0.16%	59
2026 Q2	$252K	Buy	+1,001	New	+$215K	0.16%	58

Other funds holding ABBV

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Planning Strategies's ABBV Position: Q3 2026 in Review

Planning Strategies increased its AbbVie (ABBV) stake by 0.9% in Q3 2026, buying an estimated $2.31K and bringing the position to 1,010 shares worth $264K. The position accounts for 0.16% of the portfolio, ranked #59.

Planning Strategies first reported a position in ABBV in Q2 2026 and has held it in 2 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Planning Strategies held 1,010 shares of AbbVie worth $264K as of Q3 2026.
Planning Strategies bought 9 AbbVie shares in Q3 2026, an estimated $2.31K.
AbbVie made up 0.16% of Planning Strategies's portfolio in Q3 2026, its #59 holding.
Planning Strategies first reported a position in AbbVie in Q2 2026 and has held it in 2 quarters since.
3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Planning Strategies's 13F filing for Q3 2026, filed 2 Oct 2026.